At AACR 2026, one message became clear: oncology drug development is entering a new era defined by smarter decision-making, integrated platforms, and increasingly precise therapeutic strategies. In this CrownCast episode, Crown Bioscience experts shared their perspectives from the conference, highlighting the technologies, modalities, and translational approaches that are poised to shape the future of cancer research.
From AI-enabled target discovery to spatial biology and next-generation therapeutic modalities, the discussions reflected a rapidly evolving ecosystem where innovation is no longer incremental. Instead, the industry is moving toward highly integrated workflows designed to accelerate development timelines, reduce risk, and improve patient outcomes.
More episodes from "CrownCast"



Don't miss an episode of “CrownCast” and subscribe to it in the GetPodcast app.








